[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertension-systolic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertension-systolic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,70,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100520674","bradycardia-pacemaker-with-av-interval-modulation-for-blood-pressure-treatment-100520674",false,"NCT06059638","BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT","BACKBEAT","Inclusion Criteria:\n\n1. Patient has or is indicated for a dual-chamber pacemaker. Visit 1 can be performed within 30 days prior to a planned implant of a Medtronic Astra\u002FAzure dual-chamber pacemaker system or at any time thereafter\n2. On a stable antihypertension treatment regimen with at least 1 class of antihypertensive drug\n3. Office SBP ≥135 mmHg and \\\u003C180 mmHg\n4. Average 24-Hour aSBP ≥130 mmHg and \\\u003C170 mmHg\n\nExclusion Criteria:\n\n1. LVEF \\\u003C50%\n2. NYHA Class III-IV\n3. History of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months\n4. Myocardial infarction (MI) within 3 months\n5. Prior percutaneous or surgical coronary, carotid, or endovascular intervention within 3 months\n6. Permanent atrial fibrillation\n7. Mitral valve regurgitation greater than or equal to grade 3\n8. Aortic stenosis with a valve area less than 1.5 cm2\n9. Has an active or prior device-based anti-hypertensive treatment (e.g., renal denervation procedure, baroreflex activation therapy)\n10. Has an existing active cardiac device or neurostimulator other than the recent Astra\u002FAzure pacemaker implant","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","INTERVENTIONAL",[23],"NA","A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra\u002FAzure pacemaker.",[26,27,28],"Hypertension","Hypertension, Systolic","Hypertension, Essential","RECRUITING","2026-05-22",{"date":32,"type":33},"2026-05-27","ACTUAL",{"date":35,"type":33},"2023-12-27",{"date":37,"type":20},"2029-08",{"name":39,"class":40},"Orchestra BioMed, Inc","INDUSTRY",129,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100639489","clinical-feasibility-of-cardiac-neuromodulation-therapy-for-heart-failure-with-preserved-ejection-fraction-100639489","NCT07598760","Clinical Feasibility of Cardiac Neuromodulation Therapy for Heart Failure With Preserved Ejection Fraction","Clinical Feasibility of Cardiac Neuromodulation Therapy (CNT) as Treatment for HFpEF","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Clinical indication for dual-chamber pacemaker implantation or replacement\n* Diagnosis of heart failure with preserved ejection fraction (HFpEF), defined as left ventricular ejection fraction ≥50%\n* History of hypertension\n* NYHA functional class II or III\n* On stable guideline-directed medical therapy\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* NYHA class IV heart failure\n* Permanent or persistent atrial fibrillation\n* Recent acute decompensated heart failure\n* Significant valvular heart disease requiring intervention\n* Severe comorbid conditions that, in the investigator's judgment, would make study participation unsafe\n* Pregnant or breastfeeding individuals",{"count":50,"type":20},20,[23],"This is an open-label pilot study to evaluate the feasibility of Cardiac Neuromodulation Therapy (CNT) in patients with high blood pressure and heart failure who require dual-chamber pacemaker implantation or replacement. The study will assess blood pressure and heart function at rest and during exercise, with and without CNT, for up to 12 months. Participants will receive the Moderato Plus device and complete scheduled follow-up visits. After study completion, CNT therapy will be discontinued and participants will return to standard medical care.",[54,55,27],"Hypertension (HTN)","Heart Failure With Preserved Ejection Fraction (HFpEF",[57,58,26],"CNT","HFpEF","NOT_YET_RECRUITING","2026-05-14",{"date":62,"type":33},"2026-05-20",{"date":64,"type":20},"2026-05-30",{"date":66,"type":20},"2028-11-30",{"name":68,"class":40},"BackBeat Medical Inc",2,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100508709","air-pollution-and-cardiovascular-disease-in-qatar-an-interventional-study-to-reduce-blood-pressure-100508709","NCT05903950","Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure","Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure: the APCIQ-BP Trial","APCIQ-BP","Inclusion Criteria:\n\n* Non-smokers (100% abstinence from use of any smoking or vaping product during the prior year)\n* Age ≥18 and less than 60 years old\n* Living in a single residence (home, apartment) located anywhere in Qatar\n* Mild systolic hypertension: screening visit systolic BP 130 to 159 mm Hg (off treatment or taking ≤ 2 BP medications that have been stable without changes during prior 4 weeks) plus ≥ 2 more additional criteria for the metabolic syndrome:\n\n  * Waist circumference ≥102 cm if male and ≥88 cm if female\n  * Fasting triglycerides ≥150 mg\u002FdL (or taking a triglyceride-lowering medication)\n  * HDL-C ≤ 40 mg\u002FdL if male and ≤ 50 mg\u002FdL if female (or taking an HDL-raising medication),\n  * Fasting glucose ≥100 mg\u002FdL\n\nExclusion Criteria:\n\n* Pregnancy (self-reported)\n* Screening visit urine positive for cotinine (NicAlert \\>100 ng\u002FmL)\n* Living with an active smoker who smokes indoors (by self-report)\n* High risk conditions that prohibit allowing home BP to be \\>130\u002F80 mm Hg during the10-week trial including any cardiovascular disease (coronary artery disease, prior stroke, heart failure, peripheral arterial disease, aneurysm) or ≥ stage 3 kidney disease (estimated glomerular filtration rate \\\u003C 60 ml\u002Fmin)\n* A medical condition placing the participant at risk from participation (per investigators)\n* Expected overnight travel outside their residence during the study\n* HEPA filter within the air conditioners of the residence (self-reported) or individual use of HEPA filter\n* Unable to comprehend\u002Fsign an informed consent\n* Lung disease requiring oxygen\n* Cancer receiving treatment\n* Screening visit: BP ≥160\u002F100 mm Hg or fasting blood glucose ≥126 mg\u002FdL and confirmed diabetes with follow-up HbA1c ≥6.5%. If glucose is elevated ≥126 mg\u002FdL but HbA1c\\\u003C6.5%, they could still participate.\n* Medication changes in past 4 weeks. If participants are on medications for high BP or hyperlipidemia, they will need to have had stable therapy during prior 10 weeks with no planned changes during the study\n* Left upper arm circumference \\>17 inches as this will make BP levels inaccurate with the home monitor used\n* Acute illness or infectious symptoms within the prior 4 weeks.","60 Years",{"count":80,"type":20},100,[23],"The main objective is to determine if in-home portable air cleaners provide persistent reductions in PM2.5 exposures and improvements in systolic blood pressure and biochemical parameters over 4-weeks in patients with metabolic syndrome residing in Qatar.",[27,84],"Metabolic Syndrome",[86,87,88],"hypertension","metabolic syndrome","air pollution","2025-07-16",{"date":91,"type":33},"2025-07-20",{"date":93,"type":33},"2024-11-03",{"date":95,"type":20},"2026-04",{"name":97,"class":98},"Weill Cornell Medical College in Qatar","OTHER",1,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100320848","treatment-of-hypertension-during-sleep-100320848","NCT03457168","Treatment of Hypertension During Sleep","A Prospective, Randomized, Open-label Clinical Trial on the Effects of Intensive Versus Conventional Control of Ambulatory-determined Asleep Systolic Blood Pressure Mean on Cardiovascular, Metabolic, and Renal Disease Risks","THADEUS","Inclusion Criteria:\n\n1. Men and women aged ≥18 years.\n2. All participants must: (i) have at randomization sleep-time hypertension according to the current ESH\u002FESC guidelines, i.e., asleep SBP mean ≥120 mmHg;1 (ii) adhere to a routine of daytime activity and nighttime sleep; and (iii) provide their written informed consent to participate into the study.\n\nExclusion Criteria:\n\n1. Pregnancy.\n2. History of drug\u002Falcohol abuse within the last two years.\n3. Night\u002Fshift-work employment.\n4. Previous history of a systemic autoimmune disease or AIDS.\n5. Evidence of a secondary form of hypertension, including coarctation of the aorta, hyperaldosteronism, renal artery stenosis, or pheochromocytoma\n6. CVD disorders (unstable angina pectoris, heart failure, life-threatening arrhythmia, atrial fibrillation, kidney failure, and grade III-IV retinopathy). Previous CVD events will not be exclusionary if full physical and work activities are maintained.\n7. Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of any drug, or, at the discretion of the investigator, might place the subject at higher risk from his\u002Fher participation in the study, or are likely to prevent the subject from complying with the requirements of the study or completing the trial period.\n8. History of malignancy including leukemia and lymphoma (but not basal cell skin cancer), or any other severe, life-threatening disease within the past five years.\n9. Inability to communicate and comply with all study requirements.\n10. Intolerance to ABPM.",{"count":109,"type":20},5320,[23],"On the basis of new evidence on the relationship between achieved office blood pressure (BP) measurements (OBPM) and the risk of cardiovascular disease (CVD) morbidity and mortality documented in the SPRINT trial, the recent 2017 guidelines of the American College of Cardiology (ACC) and the American Heart Association (AHA) have established lower values of 130\u002F80 mmHg for clinic systolic BP (SBP)\u002Fdiastolic BP (DBP) as new diagnostic thresholds for hypertension and therapeutic targets for treatment of all individuals aged ≥18 years regardless of age, sex, or concomitant complications including presence of diabetes, chronic kidney disease (CKD), or history of past CVD event. According to these guidelines, the new proposed ambulatory BP measurment (ABPM) thresholds for diagnosis of hypertension in adults are 130\u002F80 and 110\u002F65 mmHg for the awake and asleep SBP\u002FDBP means, respectively. However, the ACC\u002FAHA guidelines do not provide any scientific evidence documenting neither the equivalence between these ABPM thresholds and the 130\u002F80 mmHg cut-off values for OBPM nor the potential improved CVD event-free survival time of the proposed more intensive control of ambulatory BP.\n\nResults derived from observational prospective studies consistently document that therapeutic BP targets in hypertensive individuals, i.e., persons at increased CVD risk, should be established in terms of proper control of asleep BP. To date, no prospective randomized study has ever before evaluated which should be the adequate therapeutic ABPM target for most effective reduction of CVD risk. Accordingly, the Tratamiento de Hipertensión Arterial Durante el Sueño study (THADEUS, i.e., Treatment of Hypertension During Sleep) has been designed to prospectively evaluate if \"intensive control\" of asleep SBP mean proposed by the new ACC\u002FAHA guidelines (\\\u003C110 mmHg) in more effective than the so far its \"conventional control\" (\\\u003C120 mmHg) to reduce CVD morbidity and mortality in hypertensive individuals.",[26,27],[114,115,116,117,118,119,120],"Sleep-time hypertension","Ambulatory blood pressure monitoring","Hypertension chronotherapy","Asleep blood pressure","Cardiovascular risk","Type 2 diabetes","Chronic kidney disease","2024-12-03",{"date":123,"type":33},"2024-12-06",{"date":125,"type":33},"2019-02-01",{"date":127,"type":20},"2032-12-31",{"name":129,"class":98},"University of Vigo",9]